The present study aimed at evaluating the prevalence of the Metabolic Syndrome and at identifying its additional clinical features. RESEARCH DESIGN AND METHODS: Within a prospective population-based survey examining 888 subjects aged 40-79 y, subjects were identified fulfilling the WHO and the National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATPIII) criteria for diagnosing the Metabolic Syndrome. In these subjects and in the rest of the sample (controls), several metabolic and nonmetabolic biochemical parameters were compared. RESULTS: The prevalence of the Metabolic Syndrome by WHO criteria was 34.1% (95% CI 31.0-37.2) and by NCEP-ATPIII criteria 17.8% (15.5-20.3). The prevalence was significantly higher in older subjects and in those less physically active. Subjects with the Metabolic Syndrome either by WHO or by NCEP-ATPIII criteria showed higher levels of oxidized low-density lipoprotein, apolipoprotein B, urate, leptin, fibrinogen, leukocytes, erythrocyte sedimentation rate, GOT, gamma-GT and soluble endothelial adhesion molecules (E-selectin, vascular adhesion molecule-1 and intercellular adhesion molecule-1) and lower apolipoprotein A concentrations. Insulin resistance, as assessed by the Homeostasis Model Assessment, increased with the increase in the number of traits composing the syndrome found within the single individual. Subjects with insulin resistance had more pronounced abnormalities in several parameters, including the additional features of the syndrome (eg fibrinogen and soluble adhesion molecules). CONCLUSIONS: The Metabolic Syndrome occurs very frequently in the general population aged 40-79 y, and is associated with several additional metabolic and nonmetabolic abnormalities that likely contribute to an increased cardiovascular risk. Insulin resistance seems to play a major role in classic and additional abnormalities featuring the Metabolic Syndrome.
Introduction
In recent years other investigators and ourselves [1] [2] [3] described the cluster of multiple, partially or fully expressed, metabolic abnormalities within the single individual, and its association with hyperinsulinemia or insulin resistance. The cluster was named 'Syndrome X', 4 'Insulin Resistance Syndrome', 5 'Metabolic Syndrome' 6 or in other ways. Recently, a committee of experts of the WHO suggested that the appropriate name should be 'Metabolic Syndrome' and indicated a set of diagnostic criteria. 7 Another set of criteria was indicated by the experts of the National Cholesterol Education Program (NCEP)-Adult Treatment Panel (ATP) III. 8 The WHO and the NCEP-ATPIII criteria are going to become a reference for many researchers in this field. In this respect, it is also important to emphasize that the Metabolic Syndrome has received a sort of imprimatur by the Centers of Disease Control and Prevention of the US Department of Health and Human Services by which it was attributed a specific ICD code (ICD #277.7). It can therefore be anticipated that this diagnostic terminology will become very popular worldwide in the next future.
At present, there are few data in the literature indicating how frequent is the Metabolic Syndrome in the general population. In addition, although some biochemical abnormalities were proposed as further components of the syndrome (eg hyperuricemia), 7 it is not clearly elucidated yet which additional clinical or biochemical features could be found in individuals affected.
The aims of the present study were: (1) to establish the prevalence of the Metabolic Syndrome in a large sample from the general population of middle and advanced age; and (2) to extend its phenotypic description to other metabolic and nonmetabolic biochemical parameters.
Subjects, materials and methods

Subjects
The Bruneck Study is a cross-sectional and prospective population-based survey on atherosclerosis and its risk factors. It was carried out in Bruneck, a small town of about 13 500 people, located in northeastern Italy. As reported previously, 9 the baseline evaluation was performed between
July and November 1990 on subjects aged 40-79 y. Of the 4793 subjects of the appropriate age range, 125 men and 125 women for each age-decade (40-49, 50-59, 60-69, 70-79 years) were randomly selected and invited to participate in the study. Of the 1000 subjects invited, 936 volunteered after the purposes and modalities of the study had been carefully presented. Two subjects who were insulin-treated, 17 subjects with incomplete data collection and 29 subjects with no serum available for the measurement of insulin were excluded, which left 888 subjects (450 men and 438 women) for the current analysis. The protocol was approved by the Ethics Committee of the University of Verona. All subjects gave an informed consent.
Clinical data
The following demographic and clinical data were collected with a structured in-person interview by a specific questionnaire: sex, age, cigarette smoking, alcohol consumption, physical activity, socioeconomic status, health condition, drug consumption. In each subject, the following information about cigarette smoking was recorded: smoking status (nonsmoker, former smoker and current smoker), average number of cigarettes smoked per day, number of years of smoking and 'pack-years', that is, cigarette per day times years of smoking. 10 Alcohol consumption was quantified by asking type and average amount of alcoholic beverages ingested daily, and subjects were categorized in four categories: 0, 1-50, 51-99 and X100 g/day. 11 The level of physical activity during the leisure time was defined by using a three-categories scale: 1 ¼ no exercise at all; 2 ¼ regular physical activity for up to 2 h/week (jogging, biking, swimming, playing tennis, heavy gardening, etc); 3 ¼ regular regular physical activity for more than 2 h/week. The level of physical activity at work was defined by using a threecategories scale: 1 ¼ sedentary; 2 ¼ moderate; 3 ¼ heavy. 12 The score of physical activity at work and during the leisure time was then averaged to derive a parameter describing overall physical activity. Socioeconomic status was defined with a two-categories scale (1 ¼ low, 2 ¼ high) by collecting information about the occupational status of the person with the highest income in the household and the educational level of the proband. A high social status was assumed if the proband had had an education of X12 y and/or the occupation of the subject or his/her spouse was among those with an average monthly income of 42000 in the study area.
Physical examination data Weight (to the nearest 0.5 kg) and height (to the nearest 0.5 cm) were measured while the subjects were fasting overnight and wearing only underwear. 
Laboratory data
In the morning, after an overnight fast, venous blood was sampled for the measurement of plasma concentrations of glucose and serum concentrations of total and high-density lipoprotein (HDL) cholesterol, triglycerides, apolipoprotein A1 and B, urate, insulin, leptin, fibrinogen, GOT (AST), gamma-GT, monocyte chemoattracting protein-1 (MCP-1), E-selectin, P-selectin, vascular adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) and oxidized low-density lipoprotein (LDL). Whole blood was used to count white blood cells and to assess erythrocyte sedimentation rate (ESR). A spot urine collection was used for quantifying albumin-to-creatinine ratio. A 75 g oral glucose load was administered to all subjects but known diabetic patients in order to establish their glucose tolerance (normal, impaired, diabetic). During such test, blood was withdrawn at 120 min for the measurement of plasma glucose and serum insulin. Plasma glucose was measured within few hours after collection by a glucose-oxidase method. HbA 1c was measured by HPLC. Serum total cholesterol, HDL cholesterol, triglycerides and urate were assessed with enzymatic spectrophotometric techniques. Serum LDL cholesterol was calculated with the equation of Friedewald et al, 13 except when triglycerides exceeded 400 mg/dl (in such case LDL cholesterol was directly assessed). Serum apolipoproteins A1 and B were assessed on frozen serum with Metabolic Syndrome: epidemiology and phenotypic description E Bonora et al an immunonephelometric fixed-time method. Serum insulin and leptin were measured with radioimmunoassay. Intraand interassay coefficient of variation of insulin was 3.2 and 6.9%, respectively. MCP-1, E-selectin, P-selectin, VCAM-1, ICAM-1 and oxidized LDL were assayed by ELISA. Fibrinogen, GOT, gamma-GT, ESR and leukocytes were measured by standard and quality-controlled procedures. Microalbuminuria was assessed by radioimmunoassay.
Diagnostic criteria of the Metabolic Syndrome
The Metabolic Syndrome was diagnosed according to the most recent WHO criteria, 7 with the exception that insulin resistance was assessed by the Homeostasis Assessment Model (HOMA) instead of the glucose clamp. On the other hand, it seems hard to believe that the glucose clamp could be used in epidemiological settings or in the single individual. In this regard, fasting insulin or the HOMA seems to be a reliable alternative. As an alternative, the Metabolic Syndrome was diagnosed with the criteria indicated by the NCEP-ATPIII. 8 According to these criteria, subjects with the Metabolic Syndrome are those with any combination of three or more of the following risk determinants: (a) fasting plasma glucose X6.1 mmol/l; (b) blood pressure X130/X85 mmHg or treatment; (c) plasma triglycerides X1.7 mmol/l; (d) plasma HDL cholesterol o1.03 mmol/l in men and o1.29 mmol/l in women), (e) waist circumference 4102 cm in men or 488 cm in women.
Assessment of insulin resistance
The degree of insulin sensitivity was determined by the HOMA according to the method described by Matthews et al. 15 In particular, an insulin resistance score (HOMA-IR) was computed with the formula: fasting plasma glucose (mmol/l) times fasting serum insulin (mU/l) divided by 22.5. Low HOMA-IR values indicate a high insulin sensitivity, whereas high HOMA-IR values indicate a low insulin sensitivity (insulin resistance). In the present study, insulin resistance was defined by a HOMA-IR value equal or higher than the lower limit of top quartile of HOMA-IR distribution values in the whole sample, as suggested by the WHO. 7 In a previous paper, we addressed the reliability of the HOMA by a comparison with the euglycemic hyperinsulinemic clamp. HOMA-IR was able to explain 65% of insulin sensitivity measured by the glucose clamp and was able to rank individuals according to insulin resistance in a way similar to that the glucose clamp does. 16 
Statistical analysis
Statistical analysis was performed with the SPSS-X and BMDP software. Skewed variables were log e -transformed to improve the approximation to a gaussian distribution. Statistics included Student's t-test for unpaired data, one-way analysis of variance, analysis of covariance, w 2 test with Yates' correction for continuity and multiple linear regression. The prevalence rate of the Metabolic Syndrome was adjusted for the structure of the population of Bruneck as follows: age-and sex-specific prevalence rates, calculated in each of the 5th, 6th, 7th and 8th age decade, were multiplied by weights (number of subjects in the town of Bruneck in each given category divided by the overall number of subjects aged 40-79 y) and summed up to obtain the population-standardized rate.
Results
In the whole sample, the prevalence of the various components of the Metabolic Syndrome, as defined by the WHO criteria, 7 was as follows: impaired glucose regulation (IFG, IGT) or T2DM 22.6% (n ¼ 201), central obesity 73.6% (n ¼ 654), dyslipidemia 30.8% (n ¼ 274), hypertension 62.0% (n ¼ 551), microalbuminuria 12.0% (n ¼ 107). It is interesting to remark that only 8.1% of the sample was free of any of the above-mentioned disorders, whereas many subjects had two (29.7%), three (20.0%) or four (11.8%) disorders. Moreover, the prevalence of these disorders in the isolated form was definitely lower than the prevalence of combined disorders: isolated impaired glucose regulation or T2DM was found in 0.6% of subjects, isolated central obesity in 16.4%, isolated dyslipidemia in 1.1%, isolated hypertension in 7% and isolated microalbuminuria in 0.9%. Noteworthy, HOMA-estimated insulin resistance increased with the increase in the number of disorders composing the syndrome found within the single individual (Po0.0001) (Figure 1) . Moreover, HOMA-estimated insulin resistance was an independent predictor of HbA1c (standardized beta coefficient 0.300, Po0.001), triglycerides (0.308, Po0.001), HDL-cholesterol (À0.164, Po0.001) and systolic blood pressure (0.069, P ¼ 0.03), when it was modeled as an independent variable in a multiple linear regression analysis including also sex, age and BMI.
The crude prevalence of the Metabolic Syndrome by WHO criteria was 34.1% (95% CI 31.0-37.2%; n ¼ 303). After adjusting for the structure of the population of Bruneck, the prevalence was only slightly lower (31.7%, CI 28.6-34.8%). The prevalence was not significantly different in women and in men (35.9 vs 32.9%) but was higher in older, that is, those aged 460 y, than in younger subjects (42.8 vs 27.0%, Po0.001). The Metabolic Syndrome was not related to smoking or alcohol intake, but its prevalence was higher in subjects with low physical activity than in those more active (39.6 vs 26.7%, Po0.001).
When we used the NCEP-ATPIII criteria, the prevalence of the Metabolic Syndrome was 17.8% (15.5-20. 3). The prevalence was significantly lower than that established by WHO criteria (Po0.001). Once more, the prevalence was not different in men and women, but was higher in older than in younger subjects and in those less physically active. Table 1 summarizes data about the several metabolic and nonmetabolic biochemical parameters in subjects belonging Metabolic Syndrome: epidemiology and phenotypic description E Bonora et al to the Metabolic Syndrome category vs controls. When compared with the latter, apart from obvious differences in glucose, HOMA-IR, BMI, WHR, triglycerides, HDL cholesterol, blood pressure and microalbuminuria, subjects with the Metabolic Syndrome showed higher levels of apolipoprotein B, urate, leptin, fibrinogen, leukocytes, ESR, GOT (AST), gamma-GT, E-selectin, VCAM-1 and ICAM-1, and oxidized LDL, and lower concentrations of apolipoprotein A1. These differences were significant also after adjusting for sex, age, smoking, alcohol, physical activity and social status, and were found either with the WHO criteria or the NCEP-ATPIII criteria.
When we compared subjects in the top and in the bottom quartile of HOMA-IR score, that is, those with insulin resistance vs those more insulin sensitive, the former had higher concentrations of apolipoprotein B, urate, leptin, fibrinogen, ESR, leukocytes, GOT, gamma-GT, P-selectin, E-selectin, VCAM-1, ICAM-1 and oxidized LDL. These differences were statistically significant after adjusting for sex, age, lifestyle variables and BMI (Table 2) .
Discussion
To our knowledge, the present study provides one of the first epidemiological information on the prevalence of the Metabolic Syndrome, as diagnosed according to the most recent criteria indicated by the WHO 7 or the NCEP-ATPIII. 8 We focused on the general population aged Z40 y, as they represent the segment of the population with the highest probability to include subjects affected by the syndrome. Indeed, the main component of the Metabolic Syndrome according to WHO, that is impaired glucose regulation or diabetes, is rare in younger individuals, especially among Caucasians. 17 The prevalence of the syndrome was remarkably high. About one-third of subjects from the sample we examined, who were randomly recruited from the general population and who consisted of up to 88% of subjects invited to participate in the survey, turned out to be affected by the syndrome when we used the WHO criteria. This prevalence is apparently higher than that reported in the only other paper available in the literature in which the WHO criteria were used. In that paper, Isomaa et al 18 reported data on the prevalence of the Metabolic Syndrome in subjects with normal glucose tolerance, IFG/IGT and diabetes, separately. In subjects with normal glucose tolerance, they found a prevalence of the Metabolic Syndrome of B10% and in those with IFG/IGT or T2DM of B60 and B80%, respectively. However, such study was not population-based, so that a comparison with our study is not feasible. Moreover, subjects examined by Isomaa et al were younger than those we surveyed (mean age 50 vs 60 y) and, most importantly, these investigators used a definitely higher threshold for diagnosing hypertension (160/90 vs 140/90 mmHg).
In another recent study, the prevalence of the Metabolic Syndrome was evaluated by using the NCEP-ATPIII criteria. 8 In this study by Ford et al, 19 which was based upon the database of the Third National Health and Nutrition Examination Survey, the prevalence of the Metabolic Syndrome was 23.7%. In our database, the prevalence of the Metabolic Syndrome by using these criteria was substantially lower (17.8%). The discrepancy can be attributed to differences in the study population (eg ethnicity and lifestyle). Moreover, the prevalence of obesity, IGT and T2DM is substantially lower in Italy than in the United States. 17, [20] [21] [22] The prevalence of the Metabolic Syndrome was significantly higher and almost double with the WHO criteria as compared to those of the NCEP. This is mainly due to the inclusion of insulin resistance without impaired glucose regulation in the list of diagnostic criteria. Regardless of the criteria used, subjects with the Metabolic Syndrome are at increased risk of cardiovascular disease and, indeed, have an increased incidence of atherosclerosis and coronary heart disease. 23 Although the NCEP criteria are easier to apply, the WHO criteria might be preferable as they identify a greater number of subjects at risk. As expected, the prevalence of the Metabolic Syndrome was higher in subjects with poor physical activity. This is in agreement with the notion that physical inactivity is a risk factor of diabetes, obesity, dyslipidemia and hypertension. [24] [25] [26] [27] However, these data, as well as data on smoking and alcohol, should be taken with great caution as changes in lifestyle might have occurred after the metabolic disorders featuring the syndrome had been identified. Subjects with the Metabolic Syndrome showed several additional biochemical abnormalities that document the involvement of different tissues and physiological functions. According to these findings, one might conclude that subjects with the Metabolic Syndrome have disturbances in the coagulation (thrombophilia) and the antioxidative Metabolic Syndrome: epidemiology and phenotypic description E Bonora et al defense (increased oxidative stress), a mild chronic inflammatory state, an endothelial dysfunction as well as liver steatosis. Indeed, subjects with the Metabolic Syndrome showed higher levels of fibrinogen, oxidized LDL, ESR and leukocytes, several endothelium adhesion molecules, GOT and gamma-GT, which are markers of these disturbances. Some of these findings are in agreement with data reported by other investigators, although the latter did not focus exactly on subjects with the Metabolic Syndrome according to the WHO or the NCEP-ATPIII criteria. [28] [29] [30] [31] [32] [33] Subjects with the Metabolic Syndrome also showed higher serum leptin levels in spite of having, on average, an excess of body fat. This finding is consistent with a state of leptin resistance. In fact, leptin regulates food intake and body weight by acting primarily at the hypothalamus. 34 As a consequence, the finding of high circulating leptin in subjects with overweight/obesity, 35 is strongly suggestive of a resistance to the physiological effect of the hormone. 36 Accordingly, a high correlation was recently found between the serum levels of leptin and its biological effect. 37 The finding of an endothelial dysfunction in subjects with the Metabolic Syndrome deserves further comments. It is conceivable that the endothelial dysfunction might originate from the concurrent harmful effects exerted by hypertension, dyslipidemia and hyperglycemia. [38] [39] [40] However, the possibility that endothelial dysfunction gives rise to metabolic abnormalities rather than being the effect of the latter cannot be ruled out a priori. Indeed, as recently pointed out, 41 there are several clues of evidence suggesting that endothelial dysfunction, especially in small vessels, might play a primary role in the pathogenesis of many of the abnormalities clustering in the Metabolic Syndrome. On the other hand, endothelial dysfunction in large vessels might be one of the factors relating the Metabolic Syndrome to atherosclerosis and cardiovascular disease. We found that the degree of insulin resistance increased with the increase in the number of abnormalities composing the syndrome found in the single individual. Moreover, the comparison of the most insulin-resistant with the most insulin-sensitive subjects showed that the latter had many of the additional features of the syndrome we identified. These findings are consistent with the conclusion that insulin resistance is a common denominator and probably plays a pathogenic role in most of the abnormalities clustering in subjects with the syndrome. In this regard, our data are consistent with reports relating insulin resistance not only with diabetes, dyslipidemia, hypertension, central obesity and microalbuminuria, but also hyperuricemia, hyperleptinemia, endothelial dysfunction, inflammatory status, thrombophilia, oxidative stress and liver steatosis. [42] [43] [44] [45] [46] [47] [48] In conclusion, the coexistence of multiple metabolic disorders in the single individual, also called Metabolic Syndrome, occurs very frequently in the general population. The syndrome is associated with several nonmetabolic abnormalities documenting thrombophilia, increased oxidative stress, inflammation, endothelial dysfunction, liver steatosis and leptin resistance. Some of these abnormalities are likely to contribute to an increased risk of atherosclerosis and cardiovascular disease. The identification of subjects with the Metabolic Syndrome is conceivably useful from a clinical standpoint, as it can be anticipated that these individuals should benefit from interventions aimed at reducing their cardiovascular risk. However, public health managers should be aware that the size of the target population of such interventions is substantial in Western countries.
